Effects of Sulfonylureas on Periodontopathic Bacteria-Induced Inflammation. by Kawahara Yuri et al.
 1 
Effects of sulfonylureas on periodontopathic bacteria-induced inflammation 
 
Yuri Kawahara1, Takashi Kaneko2, Yasunori Yoshinaga1, Youichi Arita1, Keiko 
Nakamura2, Chihiro Koga2, Atsutoshi Yoshimura3, Ryuji Sakagami1 
 
1Section of Periodontology, Department of Odontology, Fukuoka Dental College, 
(Fukuoka, Japan) 
2Center for Oral Diseases, Fukuoka Dental College, (Fukuoka, Japan)  
3Department of Periodontology and Endodontology, Nagasaki University Graduate 
School of Biomedical Sciences, (Nagasaki, Japan) 
 
Abstract word count: 279 words 
Total count: 3818 words 
Total number of figures: 4 
Number of references: 37 
Key words: Interleukin-1beta, NLRP3, Inflammasomes, Caspase-1, Periodontitis, 
Glyburide, Glimepiride 
 
Corresponding author : Takashi Kaneko  
 
 2 
Abstract 
Interleukin-1β (IL-1β) is an inflammatory cytokine produced by monocytes/macrophages 
and is closely associated with periodontal diseases. The NLRP3 inflammasome is 
involved in IL-1β activation through pro-IL-1β processing and pyroptotic cell death in 
bacterial infection. Recently, glyburide, a hypoglycemic sulfonylurea, has been reported 
to reduce IL-1β activation by suppressing activation of the NLRP3 inflammasome. 
Therefore, we evaluated the possibility of targeting the NLRP3 inflammasome pathway 
by glyburide to suppress periodontal pathogen-induced inflammation. A human 
monocytes, THP-1 cells, were differentiated to macrophage-like cells by treatment with 
phorbol 12-myristate 13-acetate and stimulated by periodontopathic bacteria, 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, or Fusobacterium 
nucleatum, in the presence of glyburide. IL-1β and caspase-1 expression in the cells and 
culture supernatants were analyzed by western blotting and ELISA, and cell death was 
analyzed by the lactate dehydrogenase assay. Stimulation of THP-1 macrophage-like cells 
with every periodontopathic bacteria induced IL-1β secretion without cell death, which 
was suppressed by the NLRP3 inhibitor, MCC950, and caspase-1 inhibitor, z-YVAD-
FMK. Glyburide treatment suppressed IL-1β expression in culture supernatants and 
enhanced intracellular IL-1β expression, suggesting that glyburide may have inhibited 
IL-1β secretion. Subsequently, a periodontitis rat model was generated by injecting 
periodontal bacteria into the gingiva, which was analyzed histologically. Oral 
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administration of glyburide significantly suppressed the infiltration of inflammatory cells 
and the number of osteoclasts in the alveolar bone compared to the control. In addition to 
glyburide, glimepiride was shown to suppress the release of IL-1β from THP-1 
macrophage-like cells, while other sulfonylureas (tolbutamide and gliclazide) or other 
hypoglycemic drugs belonging to the biguanide family, such as metformin, failed to 
suppress IL-1β release. Our results suggest that pharmacological targeting of the NLRP3 
pathway may be a strategy for suppressing periodontal diseases. 
 
Introduction 
Periodontitis is a chronic inflammatory disease characterized by loss of gingival 
attachment surrounding the teeth and alveolar bone resorption, resulting in tooth loss. 
Infection of Gram-negative bacteria such as Porphyromonas gingivalis, Aggregatibacter 
actinomycetemcomitans, and Fusobacterium nucleatum and the host immune response 
against these bacteria in the periodontal tissue are involved in the pathology of 
periodontitis (Lamont et al. 2018). Interleukin (IL)-1β, one of the pro-inflammatory 
cytokines produced by monocytes/macrophages, is associated with periodontal diseases, 
since IL-1β expression has been shown to be up-regulated in the gingival crevicular fluid, 
saliva, and gingival tissue of patients with periodontitis as compared to healthy subjects 
(Tobón-Arroyave et al. 2008; Huang et al. 2015; García-Hernández et al. 2018). 
Further, it has been demonstrated that IL-1β expression is induced by bacterial stimulation 
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and its products such as lipopolysaccharide (LPS) (Wang et al. 2019). IL-1β is critical 
in host defense against bacterial pathogens, regulation of inflammatory responses, and 
osteoclastogenesis for bone resorption (SCHWARTZ et al. 1997). 
     IL-1β exerts its biological activity by binding to IL-1 receptor (IL-1R) type 1 on 
the surface of macrophages. IL-1β/IL-1R interaction induces the phosphorylation of 
several kinases to activate the transcription factor NF-κB, leading to expression of IL-1β 
and other inflammatory cytokines such as IL-6, IL-8, and TNFα (Gabay et al. 2010). 
IL-1 plays a central role in systemic inflammatory diseases, including rheumatoid arthritis 
and autoinflammatory diseases (Dinarello 2011). Targeting of the IL-1β pathway by 
biological agents such as IL-1R antagonists (IL-1RA) and anti-IL-1β antibodies has been 
shown to be effective in improving the pathologies of various inflammatory diseases 
(Hoffman et al. 2001; Ruperto et al. 2012; Dinarello and Meer 2013; Han et 
al. 2018). The NLRP3 inflammasome is a cytosolic protein complex consisting of 
NLRP3, ASC, and pro-caspase-1 and has been reported to be involved in IL-1β activation 
by bacterial infection, including P. gingivalis, A. actinomycetemcomitans, and F. 
nucleatum (Shibata 2018). Recognition of bacteria by pattern recognition receptors 
such as Toll-like receptors induces pro-IL-1β protein expression in the cytosol via NF-κB 
activation. Biologically active IL-1β is produced through the processing of pro-IL-1β by 
caspase-1, which is also processed from pro-caspase-1 by the activation of the NLRP3 
inflammasome (He et al. 2016). Caspase-1 cleaves Gasdermin D, and the cleaved N-
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terminal fragment forms small holes by forming multimers on the cell membrane, causing 
inflammatory cell death called pyroptosis (X. Liu et al. 2016). Pyroptosis has been 
hypothesized to be the cause of IL-1β release from macrophages (Brough and 
Rothwell 2007). 
     Glyburide (also known as Glibenclamide) is an oral hypoglycemic drug classified 
under sulfonylureas and widely used globally for the treatment of type II diabetes mellitus 
without serious side effects (Sola et al. 2015; Roglic and Norris 2018). Glyburide 
reduces blood glucose by inhibiting ATP-sensitive potassium channels (Sur1-Kir6.2) in 
pancreatic β cells, resulting in an increase in intracellular calcium levels and subsequently 
stimulating insulin release (Ashcroft 2005). In addition to the hypoglycemic effect, the 
anti-inflammatory role of glyburide has been shown in patients and in experimental 
animal models of inflammatory diseases such as melioidosis, cystitis, pancreatitis, and 
inflammatory bowel disease (L. Liu et al. 2016). For example, melioidosis, which is 
caused by the Gram-negative bacterium Burkholderia pseudomallei, results in bacteremia, 
abscesses in multiple organs, and causes pneumonia. Patients with melioidosis and 
diabetes treated with glyburide have shown decreased serum levels of inflammatory 
cytokines and lower mortality compared to patients without diabetes (Koh et al. 2011). 
Furthermore, it has been reported that glyburide reduces IL-1β production in mouse 
macrophages after LPS and ATP stimulation by inhibiting the NLRP3 inflammasome 
activation pathway (Lamkanfi et al. 2009). Considering the role of the NLRP3 
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inflammasome in IL-1β activation, inhibition of the NLRP3 pathway may effectively 
suppress inflammation in periodontal diseases. In this study, we evaluated the potential 
of glyburide and other sulfonylureas to control periodontal inflammation by inhibiting 
the IL-1β activation.  
 
Materials and Methods 
Bacteria 
In this study, P. gingivalis strain ATCC 33277, A. actinomycetemcomitans Y4, and F. 
nucleatum ATCC10953 were used as periodontopathic bacteria, and non-oral bacterial 
Escherichia coli MC4100 and Aerococcus viridans ATCC 10400 were used as references  
for Gram-negative and Gram-positive bacteria, respectively. Culturing conditions of these 
bacteria were described previously (Hara et al. 1996). After the washing procedure, 
these bacteria were freeze-dried and kept at -80℃. These bacteria were resuspended in 
PBS, boiled for 10 min, and sonicated before use.  
 
Cell preparation and stimulation 
THP-1, a human monocyte, was cultured in RPMI 1640 supplemented with 10% fetal 
bovine serum (Hyclone), 100 U/mL penicillin, and 100 μg/mL streptomycin. THP-1 cells 
were plated in a 96-well plate at 1  105 cells/100 µL and differentiated into macrophage-
like cells by exposure to 10 nM phorbol 12-myristate 13-acetate (PMA) for 48 h. 
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Differentiated THP-1 macrophage-like cells were stimulated with bacterial samples for 
24 h or, for NLRP3 activation, with 500 ng/mL of ultrapure E. coli LPS (Invivogen) for 
24 h, followed by 10 nM of nigericin (Sigma-Aldrich) for 45 min. Wherever indicated, 
the cells were treated with MCC950 (NLRP3 inhibitor, Cayman Chemical), z-YVAD-
FMK (caspase-1 inhibitor, BioVision) or glyburide (sigma-Aldrich). To investigate 
whether other sulfonylureas and other types of hypoglycemic drugs on NLPR3 activation, 
the cells were also pretreated with other sulfonylureas (tolbutamide, gliclazide, and 
glimepiride) (Sigma-Aldrich), or metformin (Sigma-Aldrich). None of the inhibitors and 
hypoglycemic drugs showed any negative impact on the growth of THP-1 macrophage-
like cells, as assessed by an MTT assay (Appendix Fig. 1). 
 
Enzyme-linked immunosorbent assay (ELISA) 
The amount of IL-1β proteins in the culture supernatants was measured using human-
specific IL-1β ELISA kits (R&D Systems) according to the manufacturer’s instructions. 
 
Assessment of cell death 
Lactate dehydrogenase (LDH) activity in the culture supernatants was measured using 
CytoTox 96® Non-Radioactive Cytotoxicity assay kit (Promega) according to the 
manufacturer’s instruction. Cells were lysed using lysis buffer to maximize LDH release. 
Percentage of cell death was calculated by the following equation: (sample LDH - 
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unstimulated LDH)/(maximum LDH - unstimulated LDH) × 100. 
 
Western Blotting 
THP-1 macrophage-like cells in 10-cm culture dishes (3  106 cell/10 mL) were 
stimulated with bacterial samples or nigericin in the presence or absence of glyburide. 
Cell lysates were prepared by direct lysis with lysis buffer consisting of 20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Triton X-100, and protease 
inhibitors (Complete EDTA-free, Roche). The protein content in the supernatant was 
measured by acetone precipitation and resuspension in lysis buffer. Protein concentration 
of the samples was determined using protein assay reagent (DCTM Protein Assay, Bio-
Rad Laboratories). The samples were electrophoresed under reducing conditions on a 
12.5% sodium dodecyl sulfate poly-acrylamide gel. After transfer to a PVDF membrane 
(0.2 µm), membranes were blocked with 5% BSA in TBST (0.01 M Tris-HCl pH 7.5 
containing 0.15 M NaCl, and 0.1% Tween 20) for 1 h at 22°C and subsequently incubated 
with rabbit anti-IL-β (Cell Signaling Technology), anti-caspase-1 (Abcam), or anti-β-
actin (Cell Signaling Technology) primary antibodies diluted in 5% BSA in TBST for 1 
h at RT. After washing, membranes were incubated with secondary anti-rabbit IgG-HRP 
(Cell Signaling Technology) in 5% BSA in TBST for 1 h and developed using ECL 
western blotting substrate (GE Healthcare). 
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Animals 
Sixty-four, 7-week-old male Lewis rats (Oriental Yeast) were used in this study (n = 
8/group). The rats were maintained under specific pathogen-free conditions in the 
Animal Center of Fukuoka Dental College. Animal care and experimental procedures 
were approved by the Institutional Animal Care and Use Committee of Fukuoka Dental 
College (Permission No. 16016). 
 
In vivo experimental protocol 
Appendix Fig. 2A shows the experimental protocol for the in vivo experiments. P. 
gingivalis, A. actinomycetemcomitans, or E. coli (0.6 µg/3 µL of PBS) was injected into 
the palatal gingiva of the maxillary first molar under isoflurane anesthesia every 24 h. 
Glyburide in 20% ethanol (20 mg/kg weight of rats) or vehicle (Mock) was orally 
administered to each group every 24 h using a tube. Rats were euthanized 24 h after the 
third injection of bacterial solution. 
 
Preparation of tissues 
The maxilla of each rat was removed immediately after death and fixed in 4% 
paraformaldehyde in PBS at 4°C for 10 h, decalcified with 10% EDTA for 3 weeks, and 
embedded in paraffin by the AMeX method (acetone, methyl benzoate, and xylene) (Sato 
et al. 1986). Bucco-paratal serial sections (4 μm thickness) at the central root levels from 
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the upper first molar were obtained. 
 
Histopathological and histometric studies 
Five groups of serial sections, each containing 10 subsections, were obtained from each 
specimen. The first subsection from each group was stained with hematoxylin and eosin 
(H&E) for histopathological observation. The number of infiltrated inflammatory cells in 
the 500 µm × 300 µm area of connective tissue above the bone crest was counted using 
image analysis software (Image J). The distance between the cement-enamel junction 
(CEJ) and the alveolar bone crest was measured to asses bone resorption (Appendix Fig. 
2B). 
To identify osteoclasts, the second section from each group was stained with 
tartrate-resistant acid phosphatase (TRAP) (Katayama et al. 1972). The number of TRAP-
positive cells in a 1,000-µm-wide area on the alveolar bone surface on the periodontal 
ligament side was counted under the light microscope (Appendix Fig. 2B). 
To detect IL-1β production, the third subsections from each group was 
immunohistologically stained using the VECTASTAIN Elite ABC-PO kit (Vector 
Laboratories) according to the manufacturer's instructions. In brief, sections were 
deparaffined, incubated in PBS with 0.3% Triton X-100 (PBST) for 20 min at room 
temperature, and treated with 3% hydrogen peroxide in distilled water to inhibit 
endogenous peroxidase activity. Sections were then pre-treated with 2% normal goat 
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serum in PBST for 30 min, and incubated with the primary antibodies against anti-IL-1β 
(rabbit polyclonal, 1:200, Abcam) in PBS for 1 h at room temperature. The sections were 
then incubated with biotinylated anti-rabbit antibody and ABC solution for 30 min, 
followed by treatment with 0.02% 3, 3'-diaminobenzidine tetrahydrochloride 
(ImmPACTTM DAB Peroxidase Substrate kit, Vector Laboratories). All sections were 
counterstained with hematoxylin.  
 
Statistical analyses 
Data are expressed as mean ± standard deviation. One-way ANOVA, followed by 
Tukey’s, and unpaired t-tests were used to determine statistical significance between 
groups. P values < 0.05 were considered to be statistically significant. 
 
Results 
IL-1β levels in the culture supernatants of THP-1 macrophage-like cells stimulated with 
each bacterium were measured by ELISA. All Gram-negative bacteria (including 
periodontal pathogens), but not Gram-positive A. viridans, stimulated THP-1 
macrophage-like cells to release IL-1β in a dose-dependent manner (Fig. 1A). Although 
A. actinomycetemcomitans and F. nucleatum showed comparable activity as E. coli, P. 
gingivalis showed the weakest activity among the Gram-negative bacteria. The NLRP3 
stimulator (LPS + nigericin) stimulated robust release of IL-1β (Fig. 1B). Expression 
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levels of pro- and mature forms of IL-1β and pro-caspase-1 were up-regulated in the cell 
lysate stimulated with each bacterium or LPS + nigericin, as shown by western blotting 
(Fig. 1C). The mature form of IL-1β (p17) was detected in the supernatant from cell 
cultures stimulated with every bacterium, except A. viridans, and in the supernatant of 
the LPS + nigericin stimulation group. Cleaved fragment of caspase-1 (p20) was only 
detected in the supernatant from cell cultures stimulated with LPS + nigericin. 
     Since caspase-1 activation has been reported to induce pyroptotic cell death, the 
LDH assay was conducted to determine the cell death of THP-1 macrophage-like cells 
stimulated with individual bacteria or LPS + nigericin. Although LPS + nigericin 
stimulation showed about 60% cell death, bacterial stimulation did not significantly 
induce cell death, even at the maximum bacterial concentration of 10 µg/mL (Fig. 1D). 
      To evaluate the involvement of NLRP3 or caspase-1 in the periodontal bacterial-
stimulated IL-1β release, THP-1 macrophage-like cells were pretreated with an NLRP3 
inhibitor, MCC950, or caspase-1 inhibitor, z-YVAD-FMK, before bacterial stimulation. 
Pretreatment of THP-1 macrophage-like cells with MCC950 or z-YVAD-FMK decreased 
IL-1β release stimulated by each periodontal bacterium or E. coli in a dose-dependent 
manner (Fig. 2A, B). Further, we investigated the effect of glyburide on the release and 
activation of IL-1β. Pretreatment of THP-1 macrophage-like cells with glyburide 
effectively inhibited the release of IL-1β stimulated by each bacterium or LPS + nigericin 
(Fig. 2C, D). Western blotting analysis of the cell lysate and supernatant of THP-1 
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macrophage-like cells stimulated with each bacterium or with LPS + nigericin in the 
absence or presence of glyburide has been shown in Fig 2E. Consistent with the ELISA 
results, protein level of the mature form of IL-1β (p17) in the supernatant was inhibited 
by glyburide. Further, expression of the cleaved form of caspase-1 (p20) was inhibited in 
the supernatant from cell cultures stimulated with LPS + nigericin. Interestingly, 
expression of the mature form of IL-1β (p17) in the cell lysate was increased by glyburide 
treatment. 
     Next, we evaluated the effects of glyburide administration on inflammation of 
periodontal tissue and osteoclastogenesis using an experimental rat periodontitis model, 
in which bacterial suspensions were injected into the palatal gingiva of the upper first 
molar. P. gingivalis and A. actinomycetemcomitans were used in this in vivo experiment 
because these bacteria have been shown to be closely associated with chronic 
periodontitis and aggressive periodontitis, respectively. Blood glucose levels significantly 
decreased after oral administration of glyburide on day 5, suggesting the hypoglycemic 
effect of glyburide (Appendix Fig. 3). Figure 3A shows histological findings of the 
specimen at the site of bacterial injection, and Fig. 3B shows the number of inflammatory 
cells at the evaluation site, as depicted in Appendix Fig. 2B. Although injection of PBS 
alone induced slight accumulation of inflammatory cells, injection of A. 
actinomycetemcomitans or E. coli significantly increased the number of inflammatory 
cells. Injection of P. gingivalis also increased the number of inflammatory cells, but 
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without statistical significance. Oral administration of glyburide significantly decreased 
the number of inflammatory cells in rats injected with A. actinomycetemcomitans or E. 
coli. Figures 3C and 3D show TRAP staining and histological analysis of the number of 
TRAP-positive cells on the bone surface at the periodontal ligament between the alveolar 
bone crest and 1,000 µm below the alveolar bone crest (Appendix Fig. 2B). Significantly 
increased number of TRAP-positive cells was observed in rats injected with A. 
actinomycetemcomitans or E. coli compared to Mock + PBS. Injection of P. gingivalis 
also increased the number of TRAP-positive cells, without statistical significance. Oral 
administration of glyburide significantly decreased the number of TRAP-positive cells in 
rats injected with A. actinomycetemcomitans or E. coli. Further, the distance between the 
CEJ and the alveolar bone crest was statistically increased in rats injected with A. 
actinomycetemcomitans or with E. coli, suggestive of the alveolar bone resorption. Oral 
administration of glyburide significantly decreased the distance between the CEJ and the 
alveolar bone crest in rats injected with each bacterium (Fig. 3E). Figure 3F shows 
histological immunostaining of IL-1β. Although injection of PBS alone did not induce 
significant IL-1β expression, its expression was increased in the gingiva with injection of 
P. gingivalis, A. actinomycetemcomitans, or E. coli. Oral administration of glyburide 
decreased the IL-1β expression in the gingiva of rats injected with each bacterium.  
     Furthermore, to address whether other sulfonylureas and hypoglycemic drugs 
belonging to the viganide family, such as metformin, inhibited IL-1β release similarly to 
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glyburide, we stimulated THP-1 macrophage-like cells with E. coli in the presence of 
other sulfonylureas (tolbutamide , gliclazide, and glimepiride) or metformin. Similar to 
glyburide, glimepiride suppressed IL-1β release in THP-1 macrophage-like cells 
stimulated with E. coli (Fig. 4A). In contrast, tolbutamide, gliclazide, and metformin 
failed to suppress IL-1β release, even at the highest concentration. Glimepiride inhibited 
IL-1β release from THP-1 macrophage-like cells stimulated with each of the 
periodontopathic bacteria (Fig. 4B). Conversely, tolbutamide significantly increased IL-
1β release from THP-1 macrophage-like cells stimulated with F. nucleatum, and 
gliclazide increased IL-1β release from THP-1 macrophage-like cells stimulated with A. 
actinomycetemcomitans or F. nucleatum. 
 
Discussion 
Although pro-IL-1β and pro-caspase-1 were constitutively and weakly expressed in THP-
1 macrophage-like cells, their expression was upregulated by stimulation with each of the 
periodontal bacteria used in this study. The mature forms of IL-1β (p17) and caspase-1 
(p20) were observed in the cell lysates and the supernatants only when THP-1 
macrophage-like cells were stimulated with the periodontopathic bacteria. This IL-1β 
release from THP-1 macrophage-like cells was inhibited by pretreatment with MCC950 
or z-YVAD-FMK, suggesting involvement of the NLRP3 inflammasome. These results 
are consistent with previous studies showing that periodontopathic bacterial infection 
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causes activation of the NLRP3 inflammasome and IL-1β secretion (Park et al. 2014; 
Shenker et al. 2015; Bui et al. 2016; Tan et al. 2018). 
     The mechanism underlying the suppressed activation and release of IL-1β by 
glyburide has not yet been elucidated. Since potassium efflux or even low intracellular 
potassium concentration has been reported to trigger NLRP3 activation in 
macrophages/monocytes (Pétrilli et al. 2007; Muñoz-Planillo et al. 2013), 
inhibition of ATP-sensitive potassium channels that prevent depletion of cytosolic 
potassium might be a plausible mechanism of glyburide-mediated suppression of the 
NLRP3 inflammasome (Hughes et al. 2013). However, Lamkanfi et al. demonstrated 
that ATP-sensitive potassium channels were dispensable for the inhibition of NLRP3 
inflammasome activation by LPS + ATP using mice deficient for ATP-sensitive 
potassium channels components Kir6.1, Kir6.2, or SUR2. (Lamkanfi et al. 2009). In 
addition, another sulfonylurea drug, glipizide, inhibited ATP-sensitive potassium 
channels but failed to inhibit NLRP3 inflammasome activation. Therefore, the authors 
speculated that glyburide could inhibit NLRP3 inflammasome activation specifically. In 
this study, although glyburide inhibited IL-1β (p17) release from THP-1 macrophage-like 
cells stimulated with periodontal bacteria, its protein expression was conversely 
augmented in the cell lysate, suggesting that NLRP3 activation occurs in the cytosol. In 
addition, cell death is not associated with IL-1β release by periodontal pathogen 
stimulation. These results suggest that glyburide may inhibit the secretory pathway of IL-
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1β. The reason for this discrepancy is not clear; however, differences in stimulators and 
animals used in these studies may underlie the differences. When pyroptosis does not 
occur, glyburide can inhibit IL-1β release. Since IL-1β does not contain a signal sequence, 
it does not follow the conventional endoplasmic reticulum (ER)/Golgi secretion route. 
Therefore, passive secretion by pyroptotic cell death is thought to be a major secretory 
system of IL-1β. However, several unconventional pathways have been shown for IL-1β 
release (Monteleone et al. 2015), active caspase-1 plays an important role in the 
regulation of unconventional protein secretion for multiple proteins (Keller et al. 2008). 
Therefore, caspase-1 could be inhibited by glyburide via an unconventional secretory 
pathway of IL-1β. In this study, the expression of the mature form of IL-1β (p17) in the 
cell lysate was increased by glyburide treatment, which may be the result of inhibition of 
the unconventional IL-1β secretory pathway. 
     Glyburide, which has been shown to inhibit the NLRP3 pathway, supressed 
inflammation, osteoclast formation, the alveolar bone resorption, and the IL-1β protein 
expression in the periodontal tissue of rats injected with the periodontal pathogens. 
Consistent with these results, Yamaguchi et al. reported that the gingival expression of 
proinflammatory cytokines (IL-1β and IL-18) and the alveolar bone resorption were 
significantly decreased in the NLRP3-deficient mice infected with P. gingivalis compared 
to that in the wild-type mice (Yamaguchi et al. 2016). Furthermore, expression of the 
NLRP3 inflammasome components such as NLRP3, ASC, and caspase-1 was up-
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regulated in periodontitis patients (Huang et al. 2015; García-Hernández et al. 
2018; Higuchi et al. 2019), suggesting that the NLRP3 inflammasome may play an 
important role in regulating periodontal inflammation and bone resorption.  
     We found that glimepiride also had similar activity to glyburide, while gliclazide, 
tolbutamide, and metformin, the biguanide therapeutic drugs, had no such activity. 
Consistent with this result, glimepiride was reported to reduce LPS-induced secretion of 
cytokines, including IL-1β, IL-6, and TNF-α (Ingham et al. 2014). Based on the 
chemical structure of sulfonylureas used in this study, glyburide and glimepiride 
possessed similar functional groups, benzamide and pyrrolamide, respectively. Moreover, 
the sulfonylurea backbone is an essential structure for binding to ATP-sensitive potassium 
channels, resulting in insulin release (Appendix Table 1). The presence of both benzamide 
and sulfonyl groups in glyburide was shown to be the minimum structure required to 
inhibit the NLRP3 inflammasome (Lamkanfi et al. 2009). These results suggest 
differences in the structural requirements for hypoglycemic action and the NLRP3 
inflammasome inhibition. Future efforts should focus on the development of synthetic 
compounds specifically to inhibit the NLRP3 inflammasome, but not ATP-sensitive 
potassium channels. 
     In summary, glyburide was shown to inhibit the release of mature IL-1β from THP-
1 macrophage-like cells stimulated with periodontopathic bacteria in vitro. Furthermore, 
glyburide inhibited inflammatory cell infiltration, osteoclast formation, and bone 
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resorption in experimental periodontitis rats induced by injection of periodontopathic 
bacteria. Collectively, these results suggest that the NLRP3 may be a therapeutic target to 
inhibit periodontal diseases. 
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Figure legends 
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Fig. 1 
(A, B) THP-1 macrophage-like cells stimulated with different kinds of bacteria or 500 
ng/mL of LPS for 24 h, followed by 10 µM of nigericin for 30 min. IL-1β concentrations 
in the supernatant were measured by ELISA. The closed bar and error bar represent the 
average and standard deviation, respectively. The experiments were conducted in 
triplicate for three independent experiments, and representative data have been shown in 
the figures. (C) THP-1 macrophage-like cells stimulated with different bacteria (10 
µg/mL, 24 h) or LPS (1 µg/mL, 24 h) + nigericin (10 µM, 45 min). Protein expression of 
IL-1β and caspase-1 in the supernatant and lysate was analyzed by Western blotting. The 
experiment was repeated three times. (D) THP-1 macrophage-like cells stimulated with 
different bacteria for 24 h and cell death were measured by LDH activity. The experiments 
were conducted in triplicate for three independent experiments, and representative data 
have been shown in the figures. P. g., P. gingivalis; A. a., A. actinomycetemcomitans; F. 
n., F. nucleatum; E. c., E. coli; A. v., A. viridans, Nig, nigericin. Statistical analyses were 
performed using one-factor ANOVA, followed by the Tukey’s test. *P < 0.05 vs (-), **P 
< 0.01, ***P < 0.001.  
 
Fig. 2 
(A, B) THP-1 macrophage-like cells stimulated with 10 µg/mL of different bacteria for 
24 h in the presence of (A) MCC950 and (B) Z-YVAD-FMK and IL-1β release in the 
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supernatant measured by ELISA. (C, D) THP-1 macrophage-like cells stimulated with 10 
µg/mL of different bacteria or 500 ng/mL of LPS for 24 h, followed by 10 µM of nigericin 
for 45 min in the presence of glyburide. IL-1β release in the supernatant was analyzed by 
ELISA. All ELISA experiments were conducted in triplicate for three independent 
experiments, and representative data have been shown in the figures. (E) THP-1 
macrophage-like cells stimulated with 10 µg/mL of different bacteria or 1 µg /mL of LPS 
for 24 h, followed by 10 µM of nigericin for 45 min in the presence or absence of 
glyburide. Protein expression of IL-1β and caspase-1 in the supernatant and lysate was 
analyzed by Western blotting. Western blotting was performed in three independent 
experiments, and representative data have been shown in the figures. P. g., P. gingivalis; 
A. a., A. actinomycetemcomitans; F. n., F. nucleatum; E. c., E. coli. Nig, nigericin; Gly, 
Glyburide. Statistical analyses were performed using one-factor ANOVA, followed by 
the Tukey’s test. *P < 0.05 vs DMSO, **P < 0.01, ***P < 0.001. 
 
Fig. 3 
(A, B) Histological findings of H&E staining and the number of inflammatory cells in the 
connective tissue. (C, D) Histological findings of TRAP staining and the number of 
TRAP-positive cells on the bone surface. (E) Histological findings of IL-1β 
immunological staining. (F) The distance between the cement enamel junction and the 
alveolar bone crest. P. g., P. gingivalis; A. a., A. actinomycetemcomitans; F. n., F. 
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nucleatum; E. c., E. coli. Bar = 200 µm. Statistical analysis was performed using unpaired 
t-test. *P < 0.05, **P < 0.01, ***P < 0.001 vs Mock. #P < 0.05, ##P < 0.01, ###P < 0.001 vs 
PBS/Mock. 
 
Fig. 4 
(A) THP-1 macrophage-like cells stimulated with 1 µg/mL of E. coli for 24 h in the 
presence of various sulfonylureas or metformin and IL-1β release in the supernatant 
measured by ELISA. (B) THP-1 macrophage-like cells stimulated with 1 µg/mL of P. 
gingivalis, A. actinomycetemcomitans, and F. nucleatum for 24 h in the presence of 
tolbutamide, gliclazide, or glimepiride, and IL-1β release in the supernatant measured by 
ELISA. All experiments were conducted in triplicate for three independent experiments, 
and representative data have been shown in the figures. P. g., P. gingivalis; A. a., A. 
actinomycetemcomitans; F. n., F. nucleatum; E. c., E. coli.; Tol, Tolbutamide; Glic, 
Gliclazide; Glim, Glimepiride; Met, Metformin. Statistical analyses were performed 
using one-factor ANOVA, followed by the Tukey’s test. *P < 0.05 vs DMSO, **P < 0.01, 
***P < 0.001. 
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Appendix Figure 1 
Effects of inhibitors and hypoglycemic drugs on growth of THP-1 macrophage-like cells. THP-1 
macrophage-like cells (1×105 cells/100 µL/well in 96-well plates) were stimulated with MCC950 (10 
μM), z-YVAD-fmk (2 μM), tolbutamide (100 μM), glyburide (100 μM), gliclazide (100 μM), 
glimepiride (100 μM), or metformin (5 μM). Twenty-four hours after incubation, 10 µL of the MTT 
reagent (5 mg/mL, Sigma-Aldrich) was added into the well and incubated for an additional 4 h. After 
adding 100 µL of the solubilizing solution (10% SDS in 10 mM HCl) overnight, optical density (OD) 
was measured colorimetrically at 600 nm. There were no statistically significant differences between 
samples and DMSO by one-factor ANOVA, followed by the Tukey’s test.  
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Appendix Figure 2 
(A) Schedule of in vivo experiments. Periodontitis in rats was generated by injection of P. gingivalis, 
A. actinomycetemcomitans, or E. coli into the mesial gingiva in the upper first molar. Rats were divided 
into two groups: glyburide group (20 mg/kg weight of rats via oral administration with a tube every 
24 h) and the mock group (20% Ethanol). Rats were euthanized 24 h after the third bacterial injection, 
and histological specimens of the periodontal tissues were stained by hematoxylin and eosin (H&E). 
Tartrate-resistant acid phosphatase (TRAP) was visualized enzymatically to identify osteoclasts. 
Whole blood was collected from rats on days 1 and 5. (B) Schema of histological analyses. The number 
of inflammatory cells in 500 µm × 300 µm of connective tissue above the bone crest. The distance 
between the cement-enamel junction (CEJ) to the alveolar bone crest. TRAP-positive cells on the bone 
surface of the periodontal ligament between the bone crest and the point 1,000 µm away from the bone 
crest. 
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Appendix Figure 3 
Changes in blood glucose levels of glyburide-administered rats. Glyburide in 20% ethanol (20 mg/kg) 
or 20% ethanol (mock) was orally administered to each group (8 rats / group) every 24 h using a tube. 
Each bacterial sample was injected into the gingiva of rats as described in the Materials & Methods. 
Blood samples were collected from the retro‐orbital venous plexus of the rats at baseline (Day 1) 
and before sacrifice (Day 5). Serum was prepared from the collected blood. Using 10 μL of the serum, 
the blood glucose level was measured using a Glutestace Ace R (GlucocardTM G Black, Arkray, 
Kyoto, Japan). Statistical analysis was performed using the Wilcoxon-Mann-Whitney sign-ranked test.  
P. g., P. gingivalis; A. a., A. actinomycetemcomitans; E. c., E. coli. **P < 0.01. NS: not significant. 
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Appendix Table 1 
Chemical structures of sulfonylureas used in this study. Glyburide and glimepiride, but neither 
tolbutamide nor gliclazide, could suppress IL-1β release from THP-1 macrophage-like cells stimulated 
with periodontal bacteria. Sulfonylurea, which is an essential structure for binding ATP-sensitive 
potassium channels (resulting in insulin release), is shown in red. Benzamide and pyrrolamide groups 
in glyburide and glimepiride are shown in blue. 
